News Updates
More Articles
- The Pitfalls and Promise of Cell and Gene Therapy Development: A Time for Concerted Action
- “Not Just Checking a Box”: A Call to Rethink Patient Involvement in the EU
- From Cells to Animals and Back Again: The Shifting Landscape of Cancer Efficacy and Safety Models
- Addressing Inequity: Embedding Inclusion and Diversity in UK Clinical Trials
- The Next AI Revolution: Computer System Validation
Linking Regulations with Diversity, Inclusion and New Opportunities in Decentralized Clinical Trials
In the US, the federal government has implemented a series of regulatory actions to overcome D&I deficiencies. These efforts should continue to address multiple dimensions related to the implementation of DCTs (decentralized clinical trials) enabled by DHTs (digital health technologies) and the accessibility by diverse populations.